Effects of treatment with dexamethasone plus rituximab salvage therapy in 27 patients previously allocated to dexamethasone monotherapy who failed to achieve sustained response (overall SR: platelet count ≥ 50 × 109/L; SR 100: platelet count ≥ 100 × 109/L; SR 150: platelet count ≥ 150 × 109/L)
| . | SR . | SR 100 . | SR 150 . |
|---|---|---|---|
| Platelets 50 × 109/L or greater . | Platelets 100 × 109/L or greater . | Platelets 150 × 109/L or greater . | |
| Patients | 27 | 27 | 27 |
| Responders, n (%) | 15 (56%) | 12 (44%) | 10 (37%) |
| . | SR . | SR 100 . | SR 150 . |
|---|---|---|---|
| Platelets 50 × 109/L or greater . | Platelets 100 × 109/L or greater . | Platelets 150 × 109/L or greater . | |
| Patients | 27 | 27 | 27 |
| Responders, n (%) | 15 (56%) | 12 (44%) | 10 (37%) |
SR indicates sustained response; SR 100, SR of platelet count ≥ 100 × 109/L; and SR 150, SR of platelet count ≥ 150 × 109/L.